161 related articles for article (PubMed ID: 18331669)
41. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
Sussman M; Yu J; Kamat SA; Hartry A; Legacy S; Duffy R; Aigbogun MS
J Affect Disord; 2017 Jan; 207():54-62. PubMed ID: 27693466
[TBL] [Abstract][Full Text] [Related]
42. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Wade AG; Toumi I; Hemels ME
Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
[TBL] [Abstract][Full Text] [Related]
43. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
44. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.
Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Picard H; Gilaberte I
J Affect Disord; 2012 Dec; 143(1-3):47-55. PubMed ID: 22858211
[TBL] [Abstract][Full Text] [Related]
45. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.
Nuijten MJ; Hardens M; Souêtre E
Pharmacoeconomics; 1995 Aug; 8(2):159-68. PubMed ID: 10155610
[TBL] [Abstract][Full Text] [Related]
46. Escitalopram: a review of its use in the management of major depressive disorder.
Murdoch D; Keam SJ
Drugs; 2005; 65(16):2379-404. PubMed ID: 16266205
[TBL] [Abstract][Full Text] [Related]
47. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.
Beard SM; McCrink L; Le TK; Garcia-Cebrian A; Monz B; Malik RA
Curr Med Res Opin; 2008 Feb; 24(2):385-99. PubMed ID: 18157921
[TBL] [Abstract][Full Text] [Related]
48. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
49. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
[TBL] [Abstract][Full Text] [Related]
50. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.
Hirschfeld RM; Vornik LA
J Clin Psychiatry; 2004; 65 Suppl 4():46-52. PubMed ID: 15046541
[TBL] [Abstract][Full Text] [Related]
51. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
Signorovitch J; Ramakrishnan K; Ben-Hamadi R; Yu AP; Wu EQ; Dworak H; Erder MH
Curr Med Res Opin; 2011 Jun; 27(6):1089-96. PubMed ID: 21438794
[TBL] [Abstract][Full Text] [Related]
52. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.
Wielage RC; Patel AJ; Bansal M; Lee S; Klein RW; Happich M
Arthritis Care Res (Hoboken); 2014 May; 66(5):702-8. PubMed ID: 24877251
[TBL] [Abstract][Full Text] [Related]
54. Duloxetine: a review of its use in the treatment of major depressive disorder.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
[TBL] [Abstract][Full Text] [Related]
55. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
[TBL] [Abstract][Full Text] [Related]
56. Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences.
Sicras-Mainar A; Navarro-Artieda R; Blanca-Tamayo M; Gimeno-de la Fuente V; Salvatella-Pasant J
Curr Med Res Opin; 2010 Dec; 26(12):2757-64. PubMed ID: 21034375
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.
Hemels ME; Kasper S; Walter E; Einarson TR
Curr Med Res Opin; 2004 Jun; 20(6):869-78. PubMed ID: 15200745
[TBL] [Abstract][Full Text] [Related]
58. Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a medicaid population.
Wu EQ; Ben-Hamadi R; Lu M; Beaulieu N; Yu AP; Erder MH
Manag Care; 2012 Jan; 21(1):49-58. PubMed ID: 22332457
[TBL] [Abstract][Full Text] [Related]
59. Continuation treatment of major depressive disorder: is there a case for duloxetine?
Norman TR; Olver JS
Drug Des Devel Ther; 2010 Feb; 4():19-31. PubMed ID: 20368904
[TBL] [Abstract][Full Text] [Related]
60. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
